SearchDictionaryMobileLogin

Ebstein Anomaly (Ebsteins Anomaly)

106  relevant articles (5 outcomes, 6 trials/studies) found for this Disease

Description: A congenital heart defect characterized by downward or apical displacement of the TRICUSPID VALVE, usually with the septal and posterior leaflets being attached to the wall of the RIGHT VENTRICLE. It is characterized by a huge RIGHT ATRIUM and a small and less effective right ventricle.

Also Known As:
Ebsteins Anomaly; Ebstein's Anomaly; Anomaly, Ebstein; Anomaly, Ebstein's

Relationship Network

Disease Context: Research Results

Related Diseases

1. Atrial Heart Septal Defects (Atrial Septal Defect)
2. Tachycardia (Tachyarrhythmias)
3. Pulmonary Atresia (Pulmonary Valve Atresia)
4. Tricuspid Atresia
5. Hypoplastic Left Heart Syndrome

Experts

1. Aggarwal, Sanjeev: 1 article (02/2008)
2. Humes, Richard A: 1 article (02/2008)
3. Chintala, Kavitha: 1 article (02/2008)
4. Macfarlane, A J R: 1 article (04/2007)
5. Smith, D: 1 article (04/2007)
6. Moise, S: 1 article (04/2007)
7. Nallathambi, Chandra: 1 article (01/2007)
8. Cyrus, Cyril: 1 article (01/2007)
9. Kulkarni, Snehal: 1 article (01/2007)
10. Cherian, Kotturathu Mammen: 1 article (01/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Ebstein Anomaly:
1. PlasticsIBA
2. OxygenIBA
3. One-Step dentin bonding system (One-Step)IBA
4. LithiumIBA
5. tranilast (N 5')IBA
11/01/1989 - "To determine which morphologic features are associated with early death, the complete echocardiograms and medical records of 16 consecutive patients with Ebstein's anomaly and concordant atrioventricular connections who presented in the fetal (n = 5) or neonatal (n = 11) period were reviewed"
09/01/1995 - "Other lesions identified were atrioventricular septal defect (n = 5), hypoplastic left heart syndrome (n = 4), ventricular septal defect (n = 4), Ebstein's anomaly (n = 3), coarctation of aorta (n = 2) and others (n = 9)"
09/15/1993 - "Since 1990, radiofrequency ablation of accessory atrioventricular (AV) pathways has been attempted in 10 patients (age range 3.5 months to 30 years) with congenital heart disease: Ebstein's anomaly (n = 5), heterotaxy with AV discordance (n = 3), tetralogy of Fallot (n = 1) and total anomalous pulmonary venous return (n = 1)"
04/01/1999 - "Diagnoses included pulmonary atresia with intact ventricular septum (n = 15), Ebstein anomaly (n = 5), levotransposition of the great arteries (n = 3), pulmonary stenosis with right ventricular hypoplasia (n = 2), tetralogy of Fallot (n = 3), dextrotransposition of the great arteries (n = l), and Uhl anomaly (n = l)"
07/01/1996 - "1994 50 neonates underwent cardiac surgery using CPB (n = 23 transposition of the great arteries; n = 4 pulmonary atresia; n = 6 critical pulmonary stenosis; n = 5 hypoplastic left heart syndrome; n = 3 Ebstein's anomaly; n = 2 interrupted arch with hypoplastic left ventricle; n = 2 single ventricle; n = 1 each: double outlet right ventricle, tricuspid atresia, critical aortic stenosis, rhabdo-myosarkoma, corrected transposition of the great arteries.) Thirty-one patients entered the study"
Order ALL the reference details at left...
6. Phenobarbital (Luminal)FDA Link
7. Nitric Oxide (Nitrogen Monoxide)FDA Link
8. Alprostadil (Muse)FDA LinkGeneric
9. sildenafil (Viagra)FDA Link
10. Therapeutic UsesIBA
04/01/2003 - "Diagnostic and therapeutic uses of inhaled nitric oxide in neonatal Ebstein's anomaly."
Order ALL the reference details at left...

Therapies and Procedures

1. Bioprosthesis
2. Cryosurgery
3. Prostheses and Implants (Prosthesis)
4. Fontan Procedure (Fontan Operation)
5. Electrodes (Electrode)

Best Treatments:
Research Summary Report
on Ebstein Anomaly
*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.
  • Free Updates for 1 Year
  • All 5 Outcomes
  • Top 26 Key Drugs and Biologics
  • Top 50 Key Therapies and Procedures
  • Detailed History Charts
  • Full Research Reference Details
  • Sample PDF Report on Psoriasis >>
Price:$24.00 & Delivery via PDF download
updates for 1 year
Research Interface

 

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.
  • Unlimited Disease, Drug and Therapy Search
  • 2 clicks from Disease to Drug to Evidence
  • Trial References
  • All the Positive Outcomes
  • Detailed Relationship Timeline Charts
  • Full Article Reference Details
  • Includes Mobile Interface Subscription
  • One-click to FDA Products/Patents
  • Request Institution License Details >>
Price:$490.00 access via web interface
1 year subscription
Proceed to Checkout >>
Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.
  • Access from any web enabled PDA or Phone
  • Trial references
  • All the Positive Outcomes
  • Drug and Therapy searches
  • Full Article Reference Details
  • Try Mobile Interface >>
Price:$45.00 access via "curehunter.com/m"
1 year subscription
Proceed to Checkout >>